

# Direct Oral Anticoagulant (DOAC) Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

<https://marketpublishers.com/r/DFA92F04DEF1EN.html>

Date: September 2025

Pages: 85

Price: US\$ 3,200.00 (Single User License)

ID: DFA92F04DEF1EN

## Abstracts

### Direct Oral Anticoagulant (DOAC) Market Summary

The direct oral anticoagulant (DOAC) market is a pivotal segment of the global pharmaceutical industry, providing critical therapies for preventing and treating thromboembolic disorders such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Unlike traditional anticoagulants like warfarin, DOACs offer advantages such as rapid onset of action, predictable pharmacokinetics, and reduced need for routine monitoring, making them a preferred choice for patients and healthcare providers. The market is characterized by high innovation, significant R&D investment, and a competitive landscape dominated by a few major pharmaceutical companies. By 2025, the global DOAC market is estimated to be valued between USD 25 billion and USD 35 billion, with a projected compound annual growth rate (CAGR) of 0.5% to 1.5% through 2030. This modest growth reflects a mature market facing patent expirations and increasing generic competition, balanced by steady demand driven by aging populations and rising cardiovascular disease prevalence. DOACs are a class of anticoagulant drugs that directly inhibit specific clotting factors, such as factor Xa (e.g., rivaroxaban, apixaban, edoxaban) or thrombin (e.g., dabigatran). These drugs have transformed anticoagulation therapy by offering improved safety profiles, fewer drug interactions, and ease of administration compared to vitamin K antagonists. The industry is driven by the growing burden of cardiovascular and thromboembolic conditions, particularly in aging populations, and the increasing adoption of DOACs over older therapies. However, the market is entering a phase of transition as key patents for leading DOACs, such as Bayer's Xarelto (rivaroxaban) and Bristol-Myers

Squibb/Pfizer's Eliquis (apixaban), are set to expire between 2024 and 2028, paving the way for generic and biosimilar competition. The industry is also shaped by regulatory scrutiny, pricing pressures, and the need for continuous innovation to address unmet needs, such as reversal agents for DOAC-related bleeding events.

## Regional Market Trends

The DOAC market exhibits varied growth dynamics across regions, influenced by healthcare infrastructure, reimbursement policies, and disease prevalence.

**North America:** The United States dominates this region, driven by high healthcare spending and widespread adoption of DOACs for atrial fibrillation and other indications. The region's CAGR is estimated at 0.3%–1.2% through 2030, reflecting a mature market with stable demand but increasing generic penetration post-patent expirations.

**Europe:** Countries like Germany, France, and the United Kingdom are key markets, with a CAGR of 0.5%–1.5%. Growth is supported by aging populations and robust healthcare systems, but pricing pressures and generic competition limit upside potential.

**Asia-Pacific:** Japan and China lead this region, with a CAGR of 1.0%–2.5%. Japan's advanced healthcare system drives demand for premium DOACs, while China's expanding middle class and improving access to healthcare boost market growth. India also shows potential due to rising cardiovascular disease awareness.

**Latin America:** Brazil and Mexico are key markets, with a CAGR of 0.5%–1.8%. Growth is driven by increasing healthcare access and demand for modern anticoagulants, though economic constraints and generic competition temper expansion.

**Middle East and Africa (MEA):** The region, including countries like Saudi Arabia and South Africa, has a CAGR of 0.8%–2.0%. Growth is supported by improving healthcare infrastructure, but limited access to advanced therapies and affordability issues constrain market potential.

## Type Analysis

The DOAC market is segmented by drug type, each with distinct characteristics and growth trends.

**Rivaroxaban:** Marketed as Xarelto by Bayer, rivaroxaban is a factor Xa inhibitor widely used for stroke prevention and thrombosis treatment.

**Apixaban:** Sold as Eliquis by Bristol-Myers Squibb and Pfizer, apixaban is a leading DOAC due to its favorable safety profile.

**Edoxaban:** Marketed as Savaysa by Daiichi Sankyo. Its adoption is growing in specific markets like Japan, but its smaller market share limits overall growth.

**Dabigatran:** Sold as Pradaxa by Boehringer Ingelheim, dabigatran is a thrombin inhibitor. Patent expirations have already led to generic competition, constraining growth.

**Others:** This includes emerging DOACs and generics. The segment is expected to grow as generics gain traction post-patent expirations.

## Company Profiles

**Pfizer:** Co-marketer of Eliquis (apixaban) with Bristol-Myers Squibb, Pfizer generated USD 7–8 billion in Eliquis revenue in 2024. Its strong commercial infrastructure supports its leadership in the DOAC market.

**Bayer:** Bayer's Xarelto (rivaroxaban) generated USD 3–4 billion in 2024, but faces generic competition due to patent expirations in 2024–2025. Bayer's global reach ensures continued market presence.

**Bristol-Myers Squibb:** A leader with Eliquis (apixaban), generating USD 13–14 billion in 2024, Bristol-Myers Squibb benefits from its strong U.S. market position but faces challenges from upcoming patent expirations.

**Boehringer Ingelheim:** Its Pradaxa (dabigatran) remains a key player, though generic competition has impacted growth. The company focuses on innovation in reversal agents to maintain relevance.

Daiichi Sankyo: Market leader for edoxaban (Savaysa), Daiichi Sankyo has a strong presence in Japan and is expanding globally, leveraging its expertise in cardiovascular therapies.

## Industry Value Chain Analysis

The DOAC value chain begins with R&D, where pharmaceutical companies invest heavily in drug discovery, clinical trials, and regulatory approvals to develop safe and effective DOACs. Manufacturing follows, involving complex processes to produce active pharmaceutical ingredients (APIs) and finished dosage forms under stringent quality standards. Distribution involves global supply chains, with companies partnering with wholesalers and pharmacies to ensure product availability. Marketing and sales efforts target healthcare providers and payers, emphasizing clinical benefits and cost-effectiveness.

Healthcare providers prescribe DOACs to patients, who access them through pharmacies or hospitals. The value chain is supported by pharmacovigilance to monitor safety and efficacy post-market. Downstream, payers and healthcare systems influence demand through reimbursement policies. The value chain is highly integrated, with leading companies controlling R&D, manufacturing, and commercialization to maximize efficiency and market share.

## Opportunities and Challenges

### Opportunities:

**Aging Population:** Rising prevalence of cardiovascular diseases in aging populations drives demand for DOACs.

**Emerging Markets:** Expanding healthcare access in Asia-Pacific and Latin America offers growth potential for DOAC adoption.

**Innovation in Reversal Agents:** Development of antidotes for DOAC-related bleeding enhances safety and market appeal.

**Patient-Centric Therapies:** DOACs' ease of use and safety profile support continued preference over traditional anticoagulants.

## Challenges:

**Patent Expirations:** Key DOAC patents expiring between 2024 and 2028 will increase generic competition, pressuring revenues.

**Pricing Pressures:** Cost containment by payers and healthcare systems limits profitability, particularly in Europe.

**Regulatory Scrutiny:** Stringent regulations and safety monitoring requirements increase development costs and market entry barriers.

**Competition from Alternatives:** Emerging therapies and non-pharmacological interventions may challenge DOAC market share.

## Contents

### **CHAPTER 1 EXECUTIVE SUMMARY**

### **CHAPTER 2 ABBREVIATION AND ACRONYMS**

### **CHAPTER 3 PREFACE**

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

### **CHAPTER 5 MARKET TREND ANALYSIS**

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

### **CHAPTER 6 INDUSTRY CHAIN ANALYSIS**

6.1 Upstream/Suppliers Analysis

6.2 Direct Oral Anticoagulant (DOAC) Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

### **CHAPTER 7 LATEST MARKET DYNAMICS**

7.1 Latest News

7.2 Merger and Acquisition

- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

## **CHAPTER 8 HISTORICAL AND FORECAST DIRECT ORAL ANTICOAGULANT (DOAC) MARKET IN NORTH AMERICA (2020-2030)**

- 8.1 Direct Oral Anticoagulant (DOAC) Market Size
- 8.2 Direct Oral Anticoagulant (DOAC) Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Direct Oral Anticoagulant (DOAC) Market Size by Type
- 8.5 Key Countries Analysis
  - 8.5.1 United States
  - 8.5.2 Canada
  - 8.5.3 Mexico

## **CHAPTER 9 HISTORICAL AND FORECAST DIRECT ORAL ANTICOAGULANT (DOAC) MARKET IN SOUTH AMERICA (2020-2030)**

- 9.1 Direct Oral Anticoagulant (DOAC) Market Size
- 9.2 Direct Oral Anticoagulant (DOAC) Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Direct Oral Anticoagulant (DOAC) Market Size by Type
- 9.5 Key Countries Analysis
  - 9.5.1 Brazil
  - 9.5.2 Argentina

## **CHAPTER 10 HISTORICAL AND FORECAST DIRECT ORAL ANTICOAGULANT (DOAC) MARKET IN ASIA & PACIFIC (2020-2030)**

- 10.1 Direct Oral Anticoagulant (DOAC) Market Size
- 10.2 Direct Oral Anticoagulant (DOAC) Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Direct Oral Anticoagulant (DOAC) Market Size by Type
- 10.5 Key Countries Analysis
  - 10.5.1 China
  - 10.5.2 India
  - 10.5.3 Japan
  - 10.5.4 South Korea
  - 10.5.5 Southeast Asia

## 10.5.6 Australia

### **CHAPTER 11 HISTORICAL AND FORECAST DIRECT ORAL ANTICOAGULANT (DOAC) MARKET IN EUROPE (2020-2030)**

- 11.1 Direct Oral Anticoagulant (DOAC) Market Size
- 11.2 Direct Oral Anticoagulant (DOAC) Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Direct Oral Anticoagulant (DOAC) Market Size by Type
- 11.5 Key Countries Analysis
  - 11.5.1 Germany
  - 11.5.2 France
  - 11.5.3 United Kingdom
  - 11.5.4 Italy
  - 11.5.5 Spain
  - 11.5.6 Belgium
  - 11.5.7 Netherlands
  - 11.5.8 Austria
  - 11.5.9 Poland
  - 11.5.10 Russia

### **CHAPTER 12 HISTORICAL AND FORECAST DIRECT ORAL ANTICOAGULANT (DOAC) MARKET IN MEA (2020-2030)**

- 12.1 Direct Oral Anticoagulant (DOAC) Market Size
- 12.2 Direct Oral Anticoagulant (DOAC) Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Direct Oral Anticoagulant (DOAC) Market Size by Type

### **CHAPTER 13 SUMMARY FOR GLOBAL DIRECT ORAL ANTICOAGULANT (DOAC) MARKET (2020-2025)**

- 13.1 Direct Oral Anticoagulant (DOAC) Market Size
- 13.2 Direct Oral Anticoagulant (DOAC) Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Direct Oral Anticoagulant (DOAC) Market Size by Type

### **CHAPTER 14 GLOBAL DIRECT ORAL ANTICOAGULANT (DOAC) MARKET FORECAST (2025-2030)**

- 14.1 Direct Oral Anticoagulant (DOAC) Market Size Forecast
- 14.2 Direct Oral Anticoagulant (DOAC) Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Direct Oral Anticoagulant (DOAC) Type Forecast

## **CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS**

### 15.1 Pfizer

- 15.1.1 Company Profile
- 15.1.2 Main Business and Direct Oral Anticoagulant (DOAC) Information
- 15.1.3 SWOT Analysis of Pfizer
- 15.1.4 Pfizer Direct Oral Anticoagulant (DOAC) Revenue, Gross Margin and Market Share (2020-2025)

### 15.2 Bayer

- 15.2.1 Company Profile
- 15.2.2 Main Business and Direct Oral Anticoagulant (DOAC) Information
- 15.2.3 SWOT Analysis of Bayer
- 15.2.4 Bayer Direct Oral Anticoagulant (DOAC) Revenue, Gross Margin and Market Share (2020-2025)

### 15.3 Bristol-Myers Squibb

- 15.3.1 Company Profile
- 15.3.2 Main Business and Direct Oral Anticoagulant (DOAC) Information
- 15.3.3 SWOT Analysis of Bristol-Myers Squibb
- 15.3.4 Bristol-Myers Squibb Direct Oral Anticoagulant (DOAC) Revenue, Gross Margin and Market Share (2020-2025)

### 15.4 Boehringer Ingelheim

- 15.4.1 Company Profile
- 15.4.2 Main Business and Direct Oral Anticoagulant (DOAC) Information
- 15.4.3 SWOT Analysis of Boehringer Ingelheim
- 15.4.4 Boehringer Ingelheim Direct Oral Anticoagulant (DOAC) Revenue, Gross Margin and Market Share (2020-2025)

### 15.5 Daiichi Sankyo

- 15.5.1 Company Profile
- 15.5.2 Main Business and Direct Oral Anticoagulant (DOAC) Information
- 15.5.3 SWOT Analysis of Daiichi Sankyo
- 15.5.4 Daiichi Sankyo Direct Oral Anticoagulant (DOAC) Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

## Tables & Figures

### TABLES AND FIGURES

Table Abbreviation and Acronyms

Table Research Scope of Direct Oral Anticoagulant (DOAC) Report

Table Data Sources of Direct Oral Anticoagulant (DOAC) Report

Table Major Assumptions of Direct Oral Anticoagulant (DOAC) Report

Figure Market Size Estimated Method

Figure Major Forecasting Factors

Figure Direct Oral Anticoagulant (DOAC) Picture

Table Direct Oral Anticoagulant (DOAC) Classification

Table Direct Oral Anticoagulant (DOAC) Applications

Table Drivers of Direct Oral Anticoagulant (DOAC) Market

Table Restraints of Direct Oral Anticoagulant (DOAC) Market

Table Opportunities of Direct Oral Anticoagulant (DOAC) Market

Table Threats of Direct Oral Anticoagulant (DOAC) Market

Table Raw Materials Suppliers

Table Different Production Methods of Direct Oral Anticoagulant (DOAC)

Table Cost Structure Analysis of Direct Oral Anticoagulant (DOAC)

Table Key End Users

Table Latest News of Direct Oral Anticoagulant (DOAC) Market

Table Merger and Acquisition

Table Planned/Future Project of Direct Oral Anticoagulant (DOAC) Market

Table Policy of Direct Oral Anticoagulant (DOAC) Market

Table 2020-2030 North America Direct Oral Anticoagulant (DOAC) Market Size

Figure 2020-2030 North America Direct Oral Anticoagulant (DOAC) Market Size and CAGR

Table 2020-2030 North America Direct Oral Anticoagulant (DOAC) Market Size by Application

Table 2020-2025 North America Direct Oral Anticoagulant (DOAC) Key Players Revenue

Table 2020-2025 North America Direct Oral Anticoagulant (DOAC) Key Players Market Share

Table 2020-2030 North America Direct Oral Anticoagulant (DOAC) Market Size by Type

Table 2020-2030 United States Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Canada Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Mexico Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 South America Direct Oral Anticoagulant (DOAC) Market Size

Figure 2020-2030 South America Direct Oral Anticoagulant (DOAC) Market Size and

**CAGR**

Table 2020-2030 South America Direct Oral Anticoagulant (DOAC) Market Size by Application

Table 2020-2025 South America Direct Oral Anticoagulant (DOAC) Key Players Revenue

Table 2020-2025 South America Direct Oral Anticoagulant (DOAC) Key Players Market Share

Table 2020-2030 South America Direct Oral Anticoagulant (DOAC) Market Size by Type

Table 2020-2030 Brazil Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Argentina Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Asia & Pacific Direct Oral Anticoagulant (DOAC) Market Size

Figure 2020-2030 Asia & Pacific Direct Oral Anticoagulant (DOAC) Market Size and CAGR

Table 2020-2030 Asia & Pacific Direct Oral Anticoagulant (DOAC) Market Size by Application

Table 2020-2025 Asia & Pacific Direct Oral Anticoagulant (DOAC) Key Players Revenue

Table 2020-2025 Asia & Pacific Direct Oral Anticoagulant (DOAC) Key Players Market Share

Table 2020-2030 Asia & Pacific Direct Oral Anticoagulant (DOAC) Market Size by Type

Table 2020-2030 China Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 India Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Japan Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 South Korea Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Southeast Asia Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Australia Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Europe Direct Oral Anticoagulant (DOAC) Market Size

Figure 2020-2030 Europe Direct Oral Anticoagulant (DOAC) Market Size and CAGR

Table 2020-2030 Europe Direct Oral Anticoagulant (DOAC) Market Size by Application

Table 2020-2025 Europe Direct Oral Anticoagulant (DOAC) Key Players Revenue

Table 2020-2025 Europe Direct Oral Anticoagulant (DOAC) Key Players Market Share

Table 2020-2030 Europe Direct Oral Anticoagulant (DOAC) Market Size by Type

Table 2020-2030 Germany Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 France Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 United Kingdom Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Italy Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Spain Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Belgium Direct Oral Anticoagulant (DOAC) Market Size

Table 2020-2030 Netherlands Direct Oral Anticoagulant (DOAC) Market Size  
Table 2020-2030 Austria Direct Oral Anticoagulant (DOAC) Market Size  
Table 2020-2030 Poland Direct Oral Anticoagulant (DOAC) Market Size  
Table 2020-2030 Russia Direct Oral Anticoagulant (DOAC) Market Size  
Table 2020-2030 MEA Direct Oral Anticoagulant (DOAC) Market Size  
Figure 2020-2030 MEA Direct Oral Anticoagulant (DOAC) Market Size and CAGR  
Table 2020-2030 MEA Direct Oral Anticoagulant (DOAC) Market Size by Application  
Table 2020-2025 MEA Direct Oral Anticoagulant (DOAC) Key Players Revenue  
Table 2020-2025 MEA Direct Oral Anticoagulant (DOAC) Key Players Market Share  
Table 2020-2030 MEA Direct Oral Anticoagulant (DOAC) Market Size by Type  
Table 2020-2025 Global Direct Oral Anticoagulant (DOAC) Market Size by Region  
Table 2020-2025 Global Direct Oral Anticoagulant (DOAC) Market Size Share by Region  
Table 2020-2025 Global Direct Oral Anticoagulant (DOAC) Market Size by Application  
Table 2020-2025 Global Direct Oral Anticoagulant (DOAC) Market Share by Application  
Table 2020-2025 Global Direct Oral Anticoagulant (DOAC) Key Vendors Revenue  
Figure 2020-2025 Global Direct Oral Anticoagulant (DOAC) Market Size and Growth Rate  
Table 2020-2025 Global Direct Oral Anticoagulant (DOAC) Key Vendors Market Share  
Table 2020-2025 Global Direct Oral Anticoagulant (DOAC) Market Size by Type  
Table 2020-2025 Global Direct Oral Anticoagulant (DOAC) Market Share by Type  
Table 2025-2030 Global Direct Oral Anticoagulant (DOAC) Market Size by Region  
Table 2025-2030 Global Direct Oral Anticoagulant (DOAC) Market Size Share by Region  
Table 2025-2030 Global Direct Oral Anticoagulant (DOAC) Market Size by Application  
Table 2025-2030 Global Direct Oral Anticoagulant (DOAC) Market Share by Application  
Table 2025-2030 Global Direct Oral Anticoagulant (DOAC) Key Vendors Revenue  
Figure 2025-2030 Global Direct Oral Anticoagulant (DOAC) Market Size and Growth Rate  
Table 2025-2030 Global Direct Oral Anticoagulant (DOAC) Key Vendors Market Share  
Table 2025-2030 Global Direct Oral Anticoagulant (DOAC) Market Size by Type  
Table 2025-2030 Direct Oral Anticoagulant (DOAC) Global Market Share by Type  
Table Pfizer Information  
Table SWOT Analysis of Pfizer  
Table 2020-2025 Pfizer Direct Oral Anticoagulant (DOAC) Revenue Gross Profit Margin  
Figure 2020-2025 Pfizer Direct Oral Anticoagulant (DOAC) Revenue and Growth Rate  
Figure 2020-2025 Pfizer Direct Oral Anticoagulant (DOAC) Market Share  
Table Bayer Information  
Table SWOT Analysis of Bayer

Table 2020-2025 Bayer Direct Oral Anticoagulant (DOAC) Revenue Gross Profit Margin

Figure 2020-2025 Bayer Direct Oral Anticoagulant (DOAC) Revenue and Growth Rate

Figure 2020-2025 Bayer Direct Oral Anticoagulant (DOAC) Market Share

Table Bristol-Myers Squibb Information

Table SWOT Analysis of Bristol-Myers Squibb

Table 2020-2025 Bristol-Myers Squibb Direct Oral Anticoagulant (DOAC) Revenue  
Gross Profit Margin

Figure 2020-2025 Bristol-Myers Squibb Direct Oral Anticoagulant (DOAC) Revenue and  
Growth Rate

Figure 2020-2025 Bristol-Myers Squibb Direct Oral Anticoagulant (DOAC) Market Share

Table Boehringer Ingelheim Information

Table SWOT Analysis of Boehringer Ingelheim

Table 2020-2025 Boehringer Ingelheim Direct Oral Anticoagulant (DOAC) Revenue  
Gross Profit Margin

Figure 2020-2025 Boehringer Ingelheim Direct Oral Anticoagulant (DOAC) Revenue  
and Growth Rate

Figure 2020-2025 Boehringer Ingelheim Direct Oral Anticoagulant (DOAC) Market  
Share

Table Daiichi Sankyo Information

Table SWOT Analysis of Daiichi Sankyo

Table 2020-2025 Daiichi Sankyo Direct Oral Anticoagulant (DOAC) Revenue Gross  
Profit Margin

Figure 2020-2025 Daiichi Sankyo Direct Oral Anticoagulant (DOAC) Revenue and  
Growth Rate

Figure 2020-2025 Daiichi Sankyo Direct Oral Anticoagulant (DOAC) Market Share

.....

## I would like to order

Product name: Direct Oral Anticoagulant (DOAC) Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

Product link: <https://marketpublishers.com/r/DFA92F04DEF1EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DFA92F04DEF1EN.html>